Search Results

MyoKardia, Inc. reported financial results for the third quarter ended September 30, 2020.

Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. “We are excited to welcome MyoKardia colleagues to Bristol Mye

MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded to help advance MyoKardia’s mission to promote understanding and treatment of the underlying drivers of serious cardiovascular diseases. More than

MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovascular Registry operated by Veradigm®, an Allscripts (NASDAQ: MDRX), business unit. The registry will support MyoKardia’s post-marketing safety and effectiveness study (DISCOVER-HCM) of mavacamten, an investigational the

LianBio announced that the company has entered into an agreement with Bristol Myers Squibb, whereby BMS has obtained LianBio’s exclusive rights to develop and commercialize mavacamten in Mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand, in conjunction with termination of the exclusive license agreement LianBio previously entered into with MyoKardia, Inc., now a wholly owned subsidiary of BMS, in August 2020 to acquire such rights.

MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 rd , 2020 at 10:30 a.m. ET. A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast will be available on the Myo

MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020.

Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced today that they have entered into a strategic collaboration to develop and commercialize mavacamten in China and other Asian te

MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry. Cynthia Ladd, who has been leading MyoKardia’s legal function as General Counsel since January 2018, will be retiring this year. “Denelle is

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a research collaboration with MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb.